GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: example 57 [US11466000B2]
Compound class:
Synthetic organic
Comment: Enozertinib is the INN for an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is claimed in Voronoi Inc. patent US11466000B2 (as example 57) [1]. Voronoi have two EGFR inhibitors listed on their development pipeline page (VRN07 and VRN11), but without a name to structure declaration we cannot be sure which one wil be aligned with this INN.
|
|
Bioactivity Comments |
Antiproliferative activity of enozertinib (example 57) against Ba/F3 NSCLC cells harbouring various EGFR mutations and the HER2 Exon 20 insertion mutation is provided in the patent [1], however no data quantifying direct inhibitor potency against enzyme tyrosine kinase activity is included. The compound inhibits growth of the cell lines with GI50 <50 nM. |